FDA label
What is Zarxio used for?
Zarxio contains filgrastim. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Zarxio lists 6 uses: Patients with Cancer Receiving Myelosuppressive Chemotherapy; Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy; Patients with Cancer Undergoing Bone Marrow Transplantation; Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy; and 2 more.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Zarxio?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Zarxio, injection, solution
Indications and Usage, quoted from the label by Sandoz Inc. (BLA125553). Cross-references to other label sections are left out.
Patients with Cancer Receiving Myelosuppressive Chemotherapy
ZARXIO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
Patients with Cancer Undergoing Bone Marrow Transplantation
ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
ZARXIO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Patients with Severe Chronic Neutropenia
ZARXIO is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
Patients Acutely Exposed to Myelosuppressive Doses of Radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
ZARXIO is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Source: DailyMed label, set id c0d1c22b-566b-4776-bdbf-00f96dad0cae, version 14, effective August 29, 2025. NDC 61314-318, one of 2 listings for this product.
Questions
What is Zarxio used for?
The FDA label for Zarxio lists 6 uses: Patients with Cancer Receiving Myelosuppressive Chemotherapy; Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy; Patients with Cancer Undergoing Bone Marrow Transplantation; Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy; and 2 more.
What drug class is Zarxio?
FDA lists filgrastim in the Leukocyte Growth Factor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.